JP2011157395A5 - - Google Patents

Download PDF

Info

Publication number
JP2011157395A5
JP2011157395A5 JP2011102847A JP2011102847A JP2011157395A5 JP 2011157395 A5 JP2011157395 A5 JP 2011157395A5 JP 2011102847 A JP2011102847 A JP 2011102847A JP 2011102847 A JP2011102847 A JP 2011102847A JP 2011157395 A5 JP2011157395 A5 JP 2011157395A5
Authority
JP
Japan
Prior art keywords
medicament according
agent
dementia
medicament
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011102847A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011157395A (ja
Filing date
Publication date
Priority claimed from GB0424563A external-priority patent/GB0424563D0/en
Application filed filed Critical
Publication of JP2011157395A publication Critical patent/JP2011157395A/ja
Publication of JP2011157395A5 publication Critical patent/JP2011157395A5/ja
Pending legal-status Critical Current

Links

JP2011102847A 2004-11-05 2011-05-02 ＶＬＰおよびアミロイドβペプチドを含む組成物 Pending JP2011157395A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0424563A GB0424563D0 (en) 2004-11-05 2004-11-05 Organic compounds
GB0424563.5 2004-11-05

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2007536128A Division JP2008515954A (ja) 2004-11-05 2005-11-03 ＶＬＰおよびアミロイドβペプチドを含む組成物

Publications (2)

Publication Number Publication Date
JP2011157395A JP2011157395A (ja) 2011-08-18
JP2011157395A5 true JP2011157395A5 (enExample) 2012-06-21

Family

ID=33523293

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007536128A Withdrawn JP2008515954A (ja) 2004-11-05 2005-11-03 ＶＬＰおよびアミロイドβペプチドを含む組成物
JP2011102847A Pending JP2011157395A (ja) 2004-11-05 2011-05-02 ＶＬＰおよびアミロイドβペプチドを含む組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2007536128A Withdrawn JP2008515954A (ja) 2004-11-05 2005-11-03 ＶＬＰおよびアミロイドβペプチドを含む組成物

Country Status (25)

Country Link
US (4) US7867499B2 (enExample)
EP (2) EP1812050A1 (enExample)
JP (2) JP2008515954A (enExample)
KR (1) KR20070073882A (enExample)
CN (1) CN101048174A (enExample)
AR (1) AR054092A1 (enExample)
AU (2) AU2005300692A1 (enExample)
BR (1) BRPI0517682A (enExample)
CA (1) CA2581300A1 (enExample)
EC (1) ECSP077415A (enExample)
GB (1) GB0424563D0 (enExample)
GT (1) GT200500313A (enExample)
IL (1) IL182692A (enExample)
MA (1) MA29020B1 (enExample)
MX (1) MX2007005430A (enExample)
MY (1) MY148584A (enExample)
NO (1) NO20072743L (enExample)
NZ (1) NZ583688A (enExample)
PE (1) PE20061047A1 (enExample)
RU (1) RU2415677C2 (enExample)
SG (1) SG170646A1 (enExample)
TN (1) TNSN07166A1 (enExample)
TW (1) TWI380825B (enExample)
WO (1) WO2006048295A1 (enExample)
ZA (1) ZA200702369B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0424563D0 (en) 2004-11-05 2004-12-08 Novartis Ag Organic compounds
TW201618806A (zh) * 2010-03-29 2016-06-01 諾華公司 有機化合物之組合物
AU2020348947B2 (en) 2019-09-16 2025-11-27 Amgen Inc. Method for external sterilization of drug delivery device
CA3208643A1 (en) 2021-01-18 2022-07-21 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0038154B1 (en) 1980-04-15 1983-09-21 Beecham Group Plc Allergens modified with polysarcosines
US5204096A (en) 1984-03-07 1993-04-20 New York Blood Center, Inc. Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipid vesicle carriers
US4722840A (en) 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
BR8707471A (pt) 1986-09-22 1988-09-13 Univ Emory Vacina e processo de preparacao
US5143726A (en) 1986-12-09 1992-09-01 The Scripps Research Institute T cell epitopes of the hepatitis B virus nucleocapsid protein
GB8903313D0 (en) 1989-02-14 1989-04-05 Wellcome Found Conjugates
GB8913737D0 (en) 1989-06-15 1989-08-02 Univ Birmingham A novel anti-allergy treatment
US5178882A (en) 1990-06-22 1993-01-12 The Regents Of The University Of California Viral decoy vaccine
US5334394A (en) 1990-06-22 1994-08-02 The Regents Of The University Of California Human immunodeficiency virus decoy
US5142726A (en) * 1991-04-03 1992-09-01 Mann Robert F Adjustable bristle length toothbrush
GB9114003D0 (en) 1991-06-28 1991-08-14 Mastico Robert A Chimaeric protein
ZA934199B (en) 1992-06-18 1994-01-10 Akzo Nv Carrier system against gnrh
US6004763A (en) 1992-09-11 1999-12-21 Institut Pasteur Antigen-carrying microparticles and their use in the induction of humoral or cellular responses
WO1994009155A1 (en) * 1992-10-13 1994-04-28 Duke University Methods of detecting alzheimer's disease
JPH08505625A (ja) 1993-01-11 1996-06-18 ダナ−ファーバー キャンサー インスティチュート 細胞毒性ｔリンパ球応答の誘導
US6180771B1 (en) 1993-12-08 2001-01-30 Immulogic Pharmaceutical Corp. Nucleic acids encoding a house dust mite allergen, Der p III, and uses therefor
US5935821A (en) 1995-01-17 1999-08-10 Board Of Trustees Of The University Of Kentucky Polynucleotides related to monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
JPH09202735A (ja) 1996-01-25 1997-08-05 Nof Corp リポソーム型アレルギー治療薬
US5786161A (en) 1996-06-06 1998-07-28 Miltenyi Biotec. Gmbh Isolation and characterization of allergen-binding cells for diagnosis of hypersensitivity
SE9604815D0 (sv) 1996-12-20 1996-12-20 Pharmacia & Upjohn Ab A metod of diagnosis
WO1998040100A1 (en) 1997-03-10 1998-09-17 Ottawa Civic Loeb Research Institute USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE AS AN ADJUVANT
US8173127B2 (en) 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
AU743827B2 (en) 1997-04-09 2002-02-07 Intellect Neurosciences, Inc. Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods of use thereof
US6169175B1 (en) 1997-08-06 2001-01-02 Centers For Disease Control And Prevention Preparation and use of recombinant influenza A virus M2 construct vaccines
US6054312A (en) 1997-08-29 2000-04-25 Selective Genetics, Inc. Receptor-mediated gene delivery using bacteriophage vectors
US6905686B1 (en) * 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
JP2002511385A (ja) 1997-12-03 2002-04-16 ニューララブ リミテッド アルツハイマー病におけるβ−アミロイド関連変化を抑制する方法
ES2207177T3 (es) 1998-02-12 2004-05-16 Apovia, Inc. Proteinas nucleo de la hepatitis b estrategicamente modificas y sus derivados.
US5990085A (en) 1998-05-04 1999-11-23 Michigan State University Inhibin-HBc fusion protein
EP1123114B1 (en) 1998-10-21 2005-12-28 THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Virus-like particles for the induction of autoantibodies
US6380364B1 (en) 1998-11-23 2002-04-30 Loyola University Of Chicago Chimeric biotin-binding papillomavirus protein
CN100534529C (zh) 1998-11-30 2009-09-02 希托斯生物技术股份公司 抗原的有序分子呈递，制备及使用的方法
IL143475A0 (en) 1998-12-04 2002-04-21 Biogen Inc Hepatitis b virus core antigen particles and vaccines and pharmaceutical compositions containing the same
IL145025A0 (en) 1999-02-25 2002-06-30 Smithkline Beecham Biolog Epitopes or mimotopes derived from the c-epsilon-3 or c-epsilon-4 domains of ige, antagonists thereof, and their therapeutic uses
US20020052311A1 (en) 1999-09-03 2002-05-02 Beka Solomon Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders
CA2349434A1 (en) 1999-09-03 2001-03-15 Ramot University Authority For Applied Research & Industrial Development Ltd. Agents and compositions and methods utilizing same useful in diagnosing and/or treating or preventing plaque forming diseases
WO2001053457A2 (en) 2000-01-21 2001-07-26 University Of Connecticut Health Center Vaccines against neurodegenerative disorders
US20030086938A1 (en) 2000-02-21 2003-05-08 Jensen Martin Roland Novel methods for down-regulation of amyloid
CA2407897A1 (en) 2000-05-05 2001-11-15 Cytos Biotechnology Ag Molecular antigen arrays and vaccines
US8519005B2 (en) * 2000-07-27 2013-08-27 Thomas N. Thomas Compositions and methods to prevent toxicity of antiinflammatory agents and enhance their efficacy
US7320793B2 (en) * 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
US7094409B2 (en) 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
MY144532A (en) * 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
WO2003024480A2 (en) 2001-09-14 2003-03-27 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
US7115266B2 (en) 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
US20030219459A1 (en) 2002-01-18 2003-11-27 Cytos Biotechnology Ag Prion protein carrier-conjugates
EP2351770A1 (en) 2002-07-17 2011-08-03 Cytos Biotechnology AG Molecular antigen arrays using a virus like particle derived from the ap205 coat protein
CN100518823C (zh) 2002-07-18 2009-07-29 赛托斯生物技术公司 半抗原-载体偶联物及其用途
US20040076645A1 (en) 2002-07-19 2004-04-22 Bachmann Martin F. Ghrelin-carrier conjugates
MXPA05000819A (es) * 2002-07-19 2005-08-29 Cytos Biotechnology Ag Composiciones de vacunas que contienen arreglos de antigeno amiloide beta 1-6.
AU2003254914A1 (en) 2002-08-12 2004-03-03 Kyowa Hakko Kogyo Co., Ltd. Amino acid-containing chewable
TW200509968A (en) * 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
TW200501962A (en) * 2003-04-01 2005-01-16 Novartis Ag Use of carbamazepine derivatives for the treatment of agitation in dementia patients
GB0424563D0 (en) * 2004-11-05 2004-12-08 Novartis Ag Organic compounds

Similar Documents

Publication Publication Date Title
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
JP2015526458A5 (enExample)
AU2018357775B2 (en) New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (PF-ILD)
HRP20160189T1 (hr) Liječenje crohnove bolesti lakvinimodom
JP2016518387A5 (enExample)
CA2883751A1 (en) Methods of treating alzheimer's disease and pharmaceutical compositions thereof
PE20040134A1 (es) Forma de dosificacion de una vez al dia de pramipexol
AR090885A1 (es) Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple
JP2012505883A5 (enExample)
RU2015103538A (ru) Способы лечения артрита
CN116712552A (zh) 用于治疗疱疹病毒诱导的病况的方法和组合物
JP2006514611A5 (enExample)
AR045289A1 (es) Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento
JP2017501140A5 (enExample)
JP2010065060A (ja) 心不全処置のための複合治療
JP2017533211A5 (enExample)
JP2019529570A5 (enExample)
JP2011157395A5 (enExample)
JP2015522603A5 (enExample)
JP2016505050A5 (enExample)
RU2008134143A (ru) Фармацевтическая композиция цитиколина, холина альфосцерата и l-карнитина (или ацетил-l-карнитина) для лечения и профилактики заболеваний центральной нервной системы и способ лечения
JP2019507786A5 (enExample)
RU2007119067A (ru) Средство для лечения синдрома раздраженного кишечника с преобладанием диареи
RU2007132971A (ru) Способы и материалы с транс-кломифеном для лечения мужского бесплодия
RU2012107483A (ru) Отамиксабан для лечения инфаркта миокарда без подъема сегмента st у пациентов пожилого возраста и пациентов с нарушенной функцией почек